2018英国国家指南：盆腔炎症性疾病的管理.pdfVIP

2018 United Kingdom National Guideline for the Management of Pelvic Inflammatory Disease 2018 United Kingdom National Guideline for the Management of Pelvic Inflammatory Disease Guideline development group: Jonathan Ross (lead author), Michelle Cole, Ceri Evans, Deirdre Lyons, Gillian Dean, Darren Cousins, PPI representative What is new in the 2018 update?  the role of Mycoplasma genitalium as an important cause of PID has become clearer and testing is recommended for women presenting with possible PID and the male partners of women with confirmed M. genitalium infection  recent evidence suggests that serious adverse events are uncommon when using moxifloxacin and its use is now recommended as a first line therapy, especially in those women with M. genitalium PID  the potential utility of MRI scanning of the pelvis in excluding differential diagnoses has been highlighted  doxycycline is now suggested as empirical treatment for male partners of women with PID to reduce exposure to macrolide antibiotics which has been associated with increased resistance in M. genitalium  references have been updated  the Grade system for reporting strength of evidence has been adopted 2 Introduction and methodology Objectives This guideline offers recommendations on the diagnostic tests, treatment regimens and health promotion principles needed for the effective management of pelvic inflammatory disease (PID) covering the management of the initial presentation, as well as how to reduce transmission, complications and future repeat infection. It is aimed primarily at women aged 16 years or older (see specific guidelines for those under 16) presenting to health care professionals working in departments offering specialist care in STI management